CLR 131 not checked
Cellectar Biosciences, Inc. · Iopofosine I 131 single · Iopofosine I 131 multiple
FollowEvery change as it happens, and a Monday email
Trials
5 active
6 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA”In the company’s words, NCT05610891 on ClinicalTrials.gov
- Tested for
- Waldenstrom Macroglobulinemia (2 trials), Waldenstrom Macroglobulinaemia, Waldenstrom's Macroglobulinaemia Refractory, Waldenstrom Macroglobulinemia With Nodal Disease, Waldenstrom's Macroglobulinemia Recurrent, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and 15 more
- Main trialPhase 3
- “The goal of this clinical trial is to evaluate whether iopofosine I 131 is more effective than the combination Rituximab-Cyclophosphamide-Dexamethasone (R-CD). The main question the study aims to answer is: • Does iopofosine I 131 work better than R-CD when looking at the length of time during and after the treatment that a patient lives with WM but it does not get worse. Participants will: * Be randomly assigned to received either iopofosine I 131 or R-CD. * If assigned to iopofosine I 131, have it administered via infusion 2 times each cycle for a total of 2 cycles (each cycle is about 3…”In the company’s words, NCT07766421 on ClinicalTrials.gov
- Other names
- Iopofosine I 131 single · Iopofosine I 131 multiple · Iopofosine I 131 fractionated · Iopofosine I · iopofosine I 131 · I-131-CLR1404 · 131I-CLR1404
Other drugs for Waldenstrom Macroglobulinemia
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- TacabrutidegBeOne Medicines (BeiGene) · Phase 1/2
- NemtabrutinibMerck & Co. · Phase 2
- MDX2003ModeX Therapeutics, An OPKO Health Company · Phase 1/2
- VenetoclaxAbbVie · Phase 2
- LacutoclaxGuangzhou Lupeng Pharmaceutical Company LTD. · Phase 1/2
Coming up4
- 30 Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- Feb 2028Phase 1 trial completes · ClinicalTrials.gov
- Jan 2032Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Jan 2032 | Evaluation of Iopofosine I 131 vs. R-CD in WM Patients | |
| Phase 2Active, not recruiting | 22 Jun 2026 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom | |
| Phase 1Active, not recruiting | 30 Jun 2027 | Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG | |
| Phase 1Active, not recruiting | 30 Jun 2027 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas | |
| Phase 1Recruiting | Feb 2028 | Phase 1 Study of CLR 125 in Triple Negative Breast Cancer | |
| Phase 1Completed | 9 Dec 2020 | Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026